吡非尼酮治疗类风湿关节炎相关间质性肺病的2期随机对照试验
TRAIL1是一项在四国34个中心开展的随机双盲安慰剂对照2期试验,纳入123例类风湿关节炎相关间质性肺病(RA-ILD)患者,评估吡非尼酮2403 mg/日与安慰剂的疗效与安全性。主要复合终点(FVC%下降≥10%或死亡)组间无显著差异,但吡非尼酮组肺功能年下降率更慢,安全性与其他吡非尼酮试验相似。
要点
- 主要复合终点无显著差异,但吡非尼酮组FVC年下降率更慢。
- 吡非尼酮组与安慰剂组治疗相关严重不良事件发生率无显著差异。
- 研究因招募缓慢和COVID-19疫情提前终止,结果需谨慎解读。
核心结论
- 吡非尼酮未显著改善主要复合终点,但减缓了RA-ILD患者FVC的下降速率。
- 吡非尼酮在RA-ILD患者中的安全性与既往吡非尼酮试验相似。
研究设计与样本
- TRAIL1为随机、双盲、安慰剂对照2期试验,在英、美、澳、加四国34个间质性肺病学术中心开展。
- 纳入18-85岁符合2010年ACR/EULAR类风湿关节炎标准且高分辨率CT显示间质性肺病的成人患者。
- 123例患者按1:1随机分配至口服吡非尼酮2403 mg/日组(63例)或安慰剂组(60例)。
- 主要终点为52周治疗期内FVC%较基线下降≥10%或死亡的复合终点发生率,在意向治疗人群中评估。
关键数值与推荐
- 吡非尼酮组治疗相关严重不良事件发生率与安慰剂组无显著差异,无治疗相关死亡。
临床怎么用
- 对于RA-ILD患者,吡非尼酮可能有助于减缓肺功能下降,但需结合个体情况谨慎使用。
- 因研究提前终止且把握度不足,结果解读需谨慎,不能据此确立常规推荐。
局限性
- 试验因招募缓慢和COVID-19疫情于2020年3月31日提前终止,导致把握度不足。
- 样本量较小(123例),可能影响次要终点和安全性分析的可靠性。
- 排除吸烟、其他已知ILD病因及临床显著COPD或哮喘患者,限制了结果的普适性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Interstitial lung disease is a known complication of rheumatoid arthritis, with a lifetime risk of developing the disease in any individual of 7·7%. We aimed to assess the safety, tolerability, and efficacy of pirfenidone for the treatment of patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD). METHODS: TRAIL1 was a randomised, double-blind, placebo-controlled, phase 2 trial done in 34 academic centres specialising in interstitial lung disease in four countries (the UK, the USA, Australia, and Canada). Adults aged 18-85 years were eligible for inclusion if they met the 2010 American College of Rheumatology and European Alliance of Associations for Rheumatology criteria for rheumatoid arthritis and had interstitial lung disease on a high-resolution CT scan imaging and, when available, lung biopsy. Exclusion criteria include smoking, clinical history of other known causes of interstitial lung disease, and coexistant clinically significant COPD or asthma. Patients were randomly assigned (1:1) to receive 2403 mg oral pirfenidone (pirfenidone group) or placebo (placebo group) daily. The primary endpoint was the incidence of the composite endpoint of a decline from baseline in percent predicted forced vital capacity (FVC%) of 10% or more or death during the 52-week treatment period assessed in the intention-to-treat population. Key secondary endpoints included change in absolute and FVC% over 52 weeks, the proportion of patients with a decline in FVC% of 10% or more, and the frequency of progression as defined by Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) in the intention-to-treat population. This study is registered with ClinicalTrials.gov, NCT02808871. FINDINGS: From May 15, 2017, to March 31, 2020, 231 patients were assessed for inclusion, of whom 123 patients were randomly assigned (63 [51%] to the pirfenidone group and 60 [49%] to the placebo group). The trial was stopped early (March 31, 2020) due to slow recruitment and the COVID-19 pandemic. The difference in the proportion of patients who met the composite primary endpoint (decline in FVC% from baseline of 10% or more or death) between the two groups was not significant (seven [11%] of 63 patients in the pirfenidone group vs nine [15%] of 60 patients in the placebo group; OR 0·67 [95% CI 0·22 to 2·03]; p=0·48). Compared with the placebo group, patients in the pirfenidone group had a slower rate of decline in lung function, measured by estimated annual change in absolute FVC (-66 vs -146; p=0·0082) and FVC% (-1·02 vs -3·21; p=0·0028). The groups were similar with regards to the decline in FVC% by 10% or more (five [8%] participants in the pirfenidone group vs seven [12%] in the placebo group; OR 0·52 [95% CI 0·14-1·90]; p=0·32) and the frequency of progression as defined by OMERACT (16 [25%] in the pirfenidone group vs 19 [32%] in the placebo group; OR 0·68 [0·30-1·54]; p=0·35). There was no significant difference in the rate of treatment-emergent serious adverse events between the two groups, and there were no treatment-related deaths. INTERPRETATION: Due to early termination of the study and underpowering, the results should be interpreted with caution. Despite not meeting the composite primary endpoint, pirfenidone slowed the rate of decline of FVC over time in patients with RA-ILD. Safety in patients with RA-ILD was similar to that seen in other pirfenidone trials. FUNDING: Genentech.
引用
- Solomon JJ, Danoff SK, Woodhead FA, et al. Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study. Lancet Respir Med. 2022. PMID: 36075242. doi:10.1016/S2213-2600(22)00260-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。